Cibus, Inc.CBUSNASDAQ

Loading chart...

Want to monitor CBUS?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

No description available.

Professional, Scientific, and Technical Services

Research and Development in Biotechnology (except Nanobiotechnology)

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

Buy Zoom And Get Anthropic Equity Now Before The IPO

ING Groep: Executing Well, But No Longer Undervalued (Rating Downgrade)

BlueScope Steel Open to Better Offers After Spurning $8.8 Billion Takeover Bid

IBM exec says Trump's Fed pick will 'overhaul' central bank policies while bringing crisis expertise

CPNG Investors Have Opportunity to Lead Coupang, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Signs a Stock Purchase Agreement for the Sale of $10 Million of Its Class A Common Stock to a Designated Third Party Identified by AIxC

Bitcoin's Fall, Why Now Is The Time For A Contrarian-Long IBIT Play

Nvidia's OpenAI investment may not be as big as once hoped, adding to a jittery tech trade

Top 15 High-Growth Dividend Stocks For February 2026

BYND Investors Have Opportunity to Lead Beyond Meat, Inc. Securities Fraud Lawsuit

Is It Time to Take a Bite Out of Apple's Stock as Revenue Growth Accelerates?

Is This CLO-Focused Fixed Income ETF a Buy After O'Donnell Financial Bought Shares Worth $6.8 Million?

Columbia Sportswear's Plunge Doesn't Make The Stock A Good Fit

A Generational Lithium Franchise in the Making: Elektros Inc. Elevates Institutional-Grade Investor Communications to Advance Critical Minerals Growth

ARDT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardent Health

Nova Eye Medical Limited (ELXMF) Q2 2026 Earnings Call Transcript

3 Reasons to Buy Uber Stock Like There's No Tomorrow

Apple Loses More AI Researchers to Meta and Google

A March Decision That Could Change Protalix BioTherapeutics Outlook

Is This Short-Term Bond ETF a Buy After Merit Financial Bought Shares Worth $8.6 Million?